Asia Fresh News

Asia Fresh Stories

Posts Tagged ‘Healthcare

Sirtex Medical Limited Launches New Global Website for SIR-Spheres(R) microspheres – a form of Selective Internal Radiation Therapy (SIRT) for Liver Tumours

leave a comment »

http://www.sirtex.com informs doctors, patients and investors about the world’s most widely used and widely studied form of SIRT for all cancers in the liver
SYDNEY /PRNewswire/ — Sirtex today unveiled http://www.sirtex.com, a new, comprehensive and easy-to-use global website for doctors, nurses, patients and investors interested in learning more about SIR-Spheres microspheres, a form of radiotherapy targeting liver tumours that is gaining increasingly wide acceptance worldwide.
“We faced some interesting challenges to make this website genuinely helpful to the wide range of people who might visit it,” said Gilman Wong, Chief Executive Officer of Sirtex Medical Limited.
“For example, administering SIR-Spheres microspheres to patients requires the skills of a team of doctors and nurses from medical oncology, hepatology, gastroenterology, liver surgery, interventional radiology, nuclear medicine and radiation oncology. Each discipline is critical to meeting the needs of a patient with liver tumours, but all have different perspectives and informational needs relative to SIR-Spheres microspheres,” he explained.
“The same holds true of patients. A patient with primary liver cancer, or hepatocellular carcinoma (HCC), has a disease that is quite different from a patient with metastatic colorectal cancer (mCRC), who may have already undergone extensive surgical, radiation and chemotherapy treatments before considering SIR-Spheres microspheres,” Mr. Wong stated.
http://www.sirtex.com has specialised content for all these diverse audiences, as well as for patient groups, through to those interested in investing in this rapidly emerging technology. Content is also regionalised for Europe, Asia-Pacific, Australia and the Americas.
“In addition to making our website useful to a cross-section of people that is quite extensive for a therapy that is itself highly specific, our other big challenge was to stay current with a rapidly growing research data base, including a number of new studies that may lead to the use of SIR-Spheres microspheres earlier and in a larger population of patients with liver cancers,” Mr. Wong added.
Visitors to http://www.sirtex.com may click through to independent sites about SIRFLOX (global) and FOXFIRE (UK), two major studies of SIR-Spheres microspheres combined with chemotherapy in mCRC patients who are at an early stage of treatment, as well as SORAMIC (Europe), SIRveNIB (Asia-Pacific) and SARAH (France), three large studies of SIR-Spheres microspheres alone or in combination with sorafenib (Nexavar®) in patients with HCC.
About Selective Internal Radiation Therapy using SIR-Spheres microspheres
Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, is a novel treatment for inoperable liver cancer that delivers high doses of radiation directly to the site of tumours. In a minimally invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumours with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.
Clinical studies have confirmed that liver cancer patients treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumour activity, and improved quality of life. SIRT has been found to shrink liver tumours more than chemotherapy alone.
Manufactured by Sirtex Medical Limited, SIR-Spheres microspheres are the only FDA-PMA approved microsphere radiation therapy for the treatment of liver metastases. Over 25,000 doses of SIR-Spheres microspheres have been supplied worldwide.
SIR-Spheres microspheres are approved for use in Australia, the European Union (CE Mark), New Zealand, Switzerland, Turkey and several other countries including in Asia (e.g. India, Korean, Singapore and Hong Kong) for the treatment of unresectable liver tumours. SIR-Spheres microspheres are also indicated in the U.S. for the treatment of non-resectable metastatic liver tumours from primary colorectal cancer in combination with intra-hepatic artery chemotherapy using floxuridine.
SIR-Spheres® is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd
Source: Sirtex Medical Limited

Written by asiafreshnews

December 12, 2012 at 10:52 am

Posted in Uncategorized

Tagged with

Sanofi Pasteur Launches IMOJEV(R) First Single-dose Vaccine Against Japanese Encephalitis in Australia

leave a comment »

MELBOURNE, Australia/PRNewswire/ —
– About 3 billion people living in Asia Pacific and travellers to the region are at risk of Japanese encephalitis –
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that IMOJEV® vaccine against Japanese encephalitis (JE) is now available in Australia. IMOJEV® is the first single dose vaccine against JE for adults in Australia. For children, one dose of IMOJEV is recommended for primary immunization; the addition of a booster dose to extend the duration of protection is being assessed by Australian Health Authorities. IMOJEV® vaccine is licensed in Australia for people from 12 months of age and older.
About 3 billion people in the Asia Pacific Region are at risk of JE[1] for which there is no specific treatment[2]. In 1995 the first outbreak in Australia was identified in the islands of the Torres Strait[3]. More recently outbreaks have also occurred in Northern Queensland. JE is the leading cause of childhood viral neurological infection and disability in Asia. JE is also a potential risk for travellers to endemic areas. Over 1.5 million Australians travel to JE endemic countries of the Asia Pacific region[4].
“IMOJEV® has shown to provide seroprotection to over 90% adults just 2 weeks after vaccination with one dose which provides strong motive to be vaccinated before traveling[5],” said Joseph Torresi MD, Head of Travel Medicine at the Austin Hospital. “There is no specific treatment for JE and vaccination is the most effective way to be protected.”
The Australian health authorities granted marketing authorization to IMOJEV® vaccine based on the review of clinical studies involving over 4,000 children and adults which demonstrated the safety of IMOJEV® vaccine and its ability to generate a protective immune response with one dose.
“IMOJEV® is an innovative vaccine that confers high-level protection against Japanese encephalitis with just one dose,” said Russell Jacobson, General Manager of Sanofi Pasteur in Australia. “IMOJEV® makes scheduling a trip in the Asia Pacific region, or other endemic areas, more convenient for business travellers, tourists and the military alike.”
About IMOJEV® vaccine
IMOJEV® vaccine is a live-attenuated JE vaccine indicated for active immunization of people 12 months and older. The clinical data supporting the use of IMOJEV® in children and in adults have been generated in multi-center studies conducted in the United States, Australia, Thailand, and the Philippines with more than 2,400 adults and 2,200 children receiving IMOJEV®. The safety and immunogenicity of IMOJEV® were compared to a licensed JE vaccine (JE-VAX®) and placebo in adults and to a control vaccine in children. A pivotal Phase III study in adults showed that a single dose of IMOJEV® is as immunogenic as three doses of JE-VAX®. A single administration of IMOJEV® elicited a protective level of neutralizing antibodies in approximately 93% and 99% of adults 14 days and 28 days after vaccine administration, respectively[5]. Over 84% of adults were still seroprotected 5 years after vaccination [6]. A Phase III study in children showed that approximately 95% of JE virus naive subjects were seroprotected 28 days after a single dose of IMOJEV®[7]. The vaccine was well tolerated and there was no indication during the clinical development program of any safety concerns. The frequency of local and systemic reactions was comparable to those reported after administration of a placebo or a control vaccine.
About Japanese encephalitis
JE is caused by a virus transmitted by mosquitoes. The disease is neuro invasive with inflammation of the brain and its membranes (meninges). Most JE virus infections are mild (fever and headache) or without apparent symptoms, but up to 1 to 200 infections results in severe disease characterized by rapid onset of high fever, headache, neck stiffness, disorientation, coma, seizures, spastic paralysis and death. The case fatality rate is 30-35% among those with disease symptoms with over 15,000 deaths per year[8]; 50% of those who survive suffer from lasting damage to the central nervous system. In areas where the JE virus is common, encephalitis occurs mainly in young children[9].
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company’s heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: http://www.sanofipasteur.com or http://www.sanofipasteur.us
1. Erlanger TE, Weiss S, Keiser J, et al. Past, present, and future of Japanese encephalitis. Emerg Infect Dis. 2009; 15:1-7.
2. Japanese encephalitis. WHO Initiative for Vaccine Research http://www.who.int/vaccine_research/diseases/vector/en/index1.html
3. Hanna JN, Ritchie SA, Phillips DA, et al. Japanese encephalitis in north Queensland, Australia, 1998. Medical Journal of Australia 1999; 170:533-6.
4. Australian Social Trends September 2010 Australian bureau of statistics catalogue no. 4102.0
5. Torresi J, McCarthy K, Feroldi E, et al. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials. Vaccine 2010; 28:7993-8000.
6. Nasveld PE, Ebringer A, Elmes N, et al. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: Randomized, double-blind, 5-year phase II study in healthy adults. Hum Vaccin 2010; 6:1038-46.
7. Feroldi E, Pancharoen C, Kosalaraksa P, et al. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: Randomized, controlled phase 3 immunogenicity and safety trial. Human Vaccines & Immunotherapeutics 2012; 8:929-37.
8. Campbell GL, Hills SL, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011; 89:766-74E
9. United Nations. The United Nations urbanization prospects: the 2005 revision. POP/DB/WUP/Rev.2005/1/F1. New York: United Nations; 2005.
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Contacts:

Global Media Relations
Pascal Barollier
T. +33-4-37-37-50-38
pascal.barollier@sanofipasteur.com
http://www.sanofipasteur.com

Australia Media Relations
Alan Brindell
T. +61-2-8666-2362
alan.brindell@sanofi.com
http://www.sanofipasteur.com.au
Source: Sanofi Pasteur

Written by asiafreshnews

December 11, 2012 at 3:08 pm

Posted in Uncategorized

Tagged with

Boston Healthcare Expands Health Economics, Pricing, and Reimbursement Consulting Practice in Asia

leave a comment »

BOSTON and HONG KONG /PRNewswire/ — Boston Healthcare announced today that it is expanding its health economics, pricing, and reimbursement consulting services with the formation of a strategic advisory practice in Asia. This enhanced presence in the Asia Pacific region enables Boston Healthcare to continue to effectively meet the reimbursement and market access needs of pharmaceutical, medical device, and diagnostics companies worldwide.
The Asia practice will be headed by Betty Su, who will become Managing Director for Boston Healthcare Associates International Hong Kong Limited, leading a team of consultants supporting clients in Hong Kong, China, and other Asia-Pacific markets, and complementing Boston Healthcare’s global reimbursement and market access advisory services.
Ms. Su specializes in market access and regulatory strategy in China, advising drug, device, and diagnostics companies on commercialization and business development opportunities. She advises biopharmaceutical, medical device, imaging and diagnostics companies in the areas of pricing and reimbursement, sales and marketing, market development, and growth strategy. Prior to her consulting role, Ms. Su held several positions at AstraZeneca in China in marketing, government affairs, and corporate communications.
“With our expanded presence in Asia, and the addition of Betty Su to our leadership team, Boston Healthcare continues to grow and enhance our strategic advisory to innovative companies around the globe,” said Joseph V. Ferrara, President of Boston Healthcare. “Hong Kong and (mainland) China are rapidly growing pharmaceutical and medical device markets, as well as emerging leaders in health care technology innovation. The expansion of our practice in Asia provides our clients with strong support in reimbursement and market access in this vital region.”
About Boston Healthcare:
Boston Healthcare helps biopharmaceutical, medical device, and diagnostics companies unlock the value of innovation in the global health care marketplace. Boston Healthcare provides reimbursement and market access strategy services, health economics and outcomes research, market analytics and pricing strategy, and business development support to health care clients worldwide.
With offices in Boston, Washington, D.C., Berlin, and Hong Kong, our unique approach, combining strategic consulting with a deep understanding of the evidence-driven value environment, gives clients a real-world edge in assessing and capturing global market and business development opportunities.
For more information please visit, http://www.bostonhealthcare.com.
Contact: Michal Taton
Company: Boston Healthcare Associates, Inc.
Phone: +1 (617) 482-4004
Source: Boston Healthcare

Written by asiafreshnews

November 27, 2012 at 5:36 pm

Posted in Uncategorized

Tagged with

FDA Approves New Non-Invasive, Non-Ionizing Radiation Therapy to Treat Pain from Bone Metastases

leave a comment »

TIRAT CARMEL, Israel /PRNewswire/ —
ExAblate(R) MRI-guided Focused Ultrasound is effective in reducing pain from bone metastases in patients who could not undergo radiation therapy; Patients reported significant improvement in well-being, function, and reduction in medication use
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate(R) MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view the Multimedia News Release, please click:
http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
Bone metastases occur when cancer cells break away from their primary site and spread to other parts of the body.
“Pain is the most common and severe symptom of bone metastases, often causing significant physical and emotional discomfort with a large impact on enjoyment of life,” says Mark Hurwitz, M.D., principal investigator of the international, multi-center, randomized study that formed the basis of InSightec’s Pre-Market Approval (PMA) application with the FDA. “Pain palliation by ExAblate can dramatically improve the quality of life for cancer patients with bone metastases. Results from the clinical study showed that ExAblate therapy significantly reduces pain caused by bone metastases. Patients also reported lasting improvement in wellbeing and function, along with a decrease in the need for medication.”
Dr. Hurwitz, who is currently Director of Thermal Oncology and Vice Chair of the Radiation Oncology Department at Thomas Jefferson University in Philadelphia, led the study during his previous tenure as Director of Regional Program Development for the Department of Radiation Oncology at Brigham and Women’s Hospital and Associate Professor of Radiation Oncology at Harvard Medical School.
According to the American Cancer Society, more than two-thirds of breast and prostate cancers that metastasize spread to the bones and this also occurs in up to 30% of metastatic lung, bladder and thyroid cancers. Up to 30 percent of patients with bone metastases either do not respond to radiation therapy or will be unable to undergo radiation for pain relief.
ExAblate combines therapeutic acoustic ultrasound waves and continuous guidance and treatment monitoring with an MRI. Physicians use the MRI to plan and guide the therapy and monitor treatment outcome. The focused ultrasound acoustic energy destroys the nerves causing the pain, resulting in rapid reduction in pain.
“The recent FDA approval of ExAblate for pain palliation will offer new options for cancer patients with crippling bone pain who are seeking pain-management options and are no longer eligible for radiation treatment,” said Dr. Kobi Vortman, President and CEO of InSightec. “This is the second FDA approval for the ExAblate technology and represents a significant milestone in our quest to expand the applications for this innovative, non-invasive therapy. It also demonstrates our continued commitment to bringing ExAblate MRI-guided focused ultrasound into broad clinical use and improving our patients’ quality of life.”
The second FDA approval for ExAblate was based on the results of an international, multi-center, randomized clinical study comparing patients with painful bone metastases undergoing palliative therapy with ExAblate to a similar group undergoing a placebo therapy. Patients who underwent the ExAblate therapy reported clinically significant pain relief and improvement of quality-of-life during follow-up three months after treatment. Over 15 centers participated in the clinical trial including Fox Chase Cancer Canter, Stanford University, UCSD, UVA, Moffitt, and Brigham and Women’s Hospital in the US as well as University of Toronto, La Sapienza University in Rome, Sheba and Rambam Medical Centers in Israel, Petrov Research Institute of Oncology and Rostov Medical University in Russia.
ExAblate is the only FDA-approved MRI-guided focused ultrasound system for treating uterine fibroids and bone metastases-related pain management. It has also received European CE marking for uterine fibroids, bone metastases, and adenomyosis. 20 hospitals in Europe and Asia-Pacific offer ExAblate as a palliative therapy for bone metastases.
InSightec will be conducting a multi-center post-marketing study of 70 US patients who suffer from painful bone metastases and will also be establishing a commercial registry to collect data about patients undergoing ExAblate therapy for the palliation of painful bone metastases.
About InSightec
InSightec Ltd. is privately held by Elbit Imaging, General Electric, and MediTech Advisors. Founded in 1999 InSightec developed ExAblate to transform MRI-guided Focused Ultrasound (MRgFUS) into a clinically viable technology. ExAblate has won several awards for innovation and its potential to help mankind including The Wall Street Journal Technology Innovation Awards and the European Union’s IST grand prize. TIME magazine recently named Focused Ultrasound as “one of 50 best inventions.” For more information about treatment centers and bone metastases please visit: http://www.insightec.com and http://www.bone-pain-palliation.co.uk
Media contact:
Lynn Golumbic, +972-4-813-1368, lynng@insightec.com
Hollister Hovey, +1-646-871-8482, hhovey@lazarpartners.com
Video: http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
Source: InSightec Ltd

Written by asiafreshnews

October 24, 2012 at 3:06 pm

Posted in Uncategorized

Tagged with

More Than 15 Years Experience: Takeda Marks one Billion Treatment Courses of Gastric Ulcer Drug Pantoprazole

leave a comment »

ZURICH/PRNewswire/ —
Takeda Pharmaceuticals International GmbH (“Takeda”) today announced that over one billion treatment courses of its gastrointestinal product pantoprazole have been administered around the world.(1) Initially launched in 1994 in Germany, pantoprazole, a proton pump inhibitor (PPI) used to treat acid related diseases, is available in more than 90 countries as a prescription treatment and over-the-counter product.
Throughout the 17 years of experience with pantoprazole, ongoing clinical trials have continued to deepen medical experience and understanding. Most recently, in April 2012 the first clinical trial evaluating tolerability, safety and efficacy of a PPI in patients with chronic peptic complaints over fifteen years of drug administration was published in the Journal Alimentary Pharmacology and Therapeutics (2) by Prof. Brunner and co-workers from the University Medical School Hannover.
The results of the analysis (n=142) demonstrated that daily pantoprazole maintenance therapy for up to 15 years for severe acid-peptic disease was effective and well tolerated. The results of the analysis (n=142) reinforced that daily Pantoprazole maintenance therapy for up to 15 years for severe acid-peptic disease is effective and well tolerated. No safety concerns were identified. No evidence of an enhanced risk for gastric carcinoma was observed in assessments of laboratory and histological parameters. A major strength of this study lies in the continuous collection of safety data and, in particular, gastric histological data over the course of 15 years of daily treatment with pantoprazole. These results provide reassuring evidence for the long-term safety of pantoprazole and underline the benefits and the favourable efficacy and safety profile of the product.
Prof. Brunner, Division of Gastroenterology and Hepatology at the University Medical School Hannover, said “The patient outcomes after 15 years of treatment makes pantoprazole one of the best researched PPIs in long-term treatment, reassuring the safety and efficacy profile of this product.”
Pantoprazole is a proton pump inhibitor used to treat the symptoms of stomach and intestinal gastric ulcers, heartburn, gastro-esophageal reflux disease (GERD) and other related gastrointestinal diseases. Pantoprazole is marketed in more than 90 countries under a variety of brand names, including Pantozol®, Somac®, Controloc®, Pantoloc® and Zurcal®. In the US, the medicine is marketed by Takeda’s partner, Pfizer Inc., under the brand name Protonix®.
In addition to pantoprazole, acquired through its merger with Nycomed, Takeda has a long heritage of focusing on the issues that affect patients living with upper gastrointestinal disorders through the development of innovative treatments.
Other PPIs marketed by the Takeda Group include: Tecta®, an advanced magnesium-salt formulation of pantoprazole, Prevacid® (lansoprazole), a well-known PPI in around 90 markets, and Dexilant®(dexlansoprazole), the first PPI with a novel dual delayed release technology.
————————————————–
1. Periodic Safety Update Report (PSUR) No. 34 – pantoprazole, October 2012
2. Brunner et al. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Alimentary Pharmacology and Therapeutics 2012; 36: 37-47
About Takeda Pharmaceuticals International GmbH
Takeda Pharmaceuticals International GmbH, headquartered in Zurich, is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As the largest pharmaceutical company in Japan and a leader in the global industry, Takeda’s mission is to strive toward better health for patients worldwide through leading innovation in medicine. It has a commercial presence in around 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Takeda is ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe. Areas of focus include cardiovascular and metabolic diseases, immunology and respiratory diseases, oncology and central nervous system diseases, among others. Through the integration of Millennium Pharmaceuticals and Nycomed, Takeda has been transforming itself, broadening its therapeutic expertise and geographic outreach.
Additional information about Takeda is available through its corporate website, http://www.takeda.com.
This press release has been issued by Takeda Pharmaceuticals International GmbH, Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon, Zurich, Switzerland.
Source: Takeda

Written by asiafreshnews

October 24, 2012 at 2:42 pm

Posted in Uncategorized

Tagged with

Health Ingredients (Hi)/Safety and Technology (S-tec) Japan 2012 Closes with Great Success

leave a comment »

Show Report: http://www.hijapan.info/eng/past_report/past_report.html
TOKYO /PRNewswire/ — Hi/S-tec Japan 2012 was held in Tokyo from 3-5 October 2012. As Asia’s largest ingredients trade show for functional and health ingredients, the 2012 show had 540 exhibitors with 830 booths and more than 380 exhibitor presentations. Furthermore, a total of 36 high profile conferences were held in conjunction with the exhibition, focusing on the latest trends in the Japanese food market and product research and development.
Heightened awareness of health issues among Japanese consumers and receptiveness to innovative products and health concepts means that Japan is at the forefront of the development and commercialisation of health foods, nutraceuticals, cosmeceuticals, supplements, natural and organic foods. High purchasing power, an aging population, and keen consumer awareness of health products is now creating perfect conditions for the manufacturers and suppliers of healthy processed foods in Japan. What’s more, people’s demand for beauty on the inside is also markedly growing. As a result, the 2012 show attracted more attention than ever.
Japan’s demand for ingredients from abroad is getting stronger as Japanese companies continually expand their lists of health-related products. Hi/S-tec Japan is now established as a global event with strong international participation. The 2012 show featured exhibitors from 16 countries and visitors from 30 countries. In addition to four country/region pavilions from the USA, Canada, South Korea and Taiwan, there were several international exhibitors from Germany, Italy, France, Switzerland, Spain, Finland, Norway, New Zealand, India, Chile and countries from West Africa. When it comes to international visitors, not only nearby Asian countries such as South Korea, China, Thailand and Malaysia were present but also countries from Oceania, North America and Europe came to the 2012 show, and the number of representative countries came out to 30, the highest since Hi/S-tec Japan started 23 years ago.
Next year the show will be held from 9-11 October 2013. Marking our 24th anniversary, this show is expected to be larger and more international. Information for next year’s show is below:
Health Ingredients (Hi)/Safety and Technology (S-tec) Japan 2013
10am-5pm, 9-11 October 2013
Venue: Tokyo Big Sight Exhibition Center – West Hall 1, 2 and Atrium, Tokyo, Japan
http://www.hijapan.info/eng
The organizer of Hi/S-tec Japan 2013 is UBM Media Co., Ltd.
Yosuke Horikawa
+81-3-5296-1017
Yosuke.Horikawa@ubm.com
Source: UBM Media Co., Ltd.

Written by asiafreshnews

October 19, 2012 at 2:32 pm

Posted in Uncategorized

Tagged with , ,

LEO Pharma Unveils New Scientific Collaboration Strategy

leave a comment »

BALLERUP, Denmark/PRNewswire/ — LEO Pharma has announced plans to establish five long-term, strategic research collaborations in four countries by the end of next year. The ambitious initiative aims to deliver new treatment options to dermatology patients – faster than ever before. The first in the series of collaborations to be announced is with Charite, one of Europe’s oldest and largest university hospitals.
Today, LEO Pharma has revealed plans to establish five long-term, strategic research collaborations from now until the end of 2013 in Australia, France, Germany and the US. The research will supplement LEO Pharma’s internal R&D activities.
Each collaboration will integrate discovery research and exploratory clinical trials to an exceptionally high degree. The unique approach will enable LEO Pharma to explore more dermatological treatment solutions at record speed – reducing the time it takes to deliver new therapeutic options.
“This marks the beginning of an exciting journey for LEO Pharma and the patients we serve. By joining forces with world-leading experts, we hope to break important, new ground in dermatology – faster than we’ve ever done before,” says Kim Kjoeller, Senior Vice President, Global Development.
“We’re entering unchartered territory. Not only will we identify and test treatment solutions that no one has explored before; we will also explore new therapeutic areas for LEO Pharma. By working at the forefront of drug discovery and development, LEO Pharma can go that extra mile to meet patient needs. We are excited about the possibilities ahead.”
The scope of the scientific collaboration strategy covers skin conditions in which LEO Pharma is al-ready active, such as psoriasis, atopic dermatitis and actinic keratosis, as well as new therapeutic areas for LEO Pharma.
Exploring itch at joint institute
LEO Pharma can already reveal details of its first collaboration: establishing a joint institute called I2DEAL, the International Institute of Dermatology and Allergy, with Charite, one of Europe’s oldest and largest university hospitals. Here, experts will conduct early exploratory clinical trials and explore the underlying mechanisms of disease in allergic and itchy skin conditions. It is the first time that the Department of Dermatology and Allergy at Charite enters into collaboration with a private pharmaceutical company to such a high degree.
Prof. Dr. Marcus Maurer, Director of Research at the Department of Dermatology and Allergy at Charite, said: “A perfect match – that’s how I’d describe our partnership with LEO Pharma. By combining our individual expertise, we can make significant advances in dermatology research and towards meeting patient needs.
“Our research will focus on itch and inflammation. We know that itchy and inflamed skin is by far the greatest burden of disease for many patients, particularly those with eczema and psoriasis. Despite this, patients lack satisfactory treatment options. Together with LEO Pharma, we aim to discover new ways to relieve patients from itchy and inflamed skin.”
Contact
Eva Juul Langlands
Corporate Communications Manager
+45 41 88 30 94
eva.langlands@leo-pharma.com
Source: LEO Pharma A/S

Written by asiafreshnews

October 5, 2012 at 9:56 am

Posted in Uncategorized

Tagged with